Skip to main content
Elsevier

Metabolomic Phenotyping for the Future of Personalized Medicine

Beyond the Biomarkers

  • 1st Edition - September 30, 2026
  • Latest edition
  • Authors: Jacopo Troisi, Martina Lombardi
  • Language: English

Metabolomic Phenotyping for the Future of Personalized Medicine: Beyond the Biomarkers takes a critical look at the advancements in the field. It begins by explaining the essential… Read more

Back to School

Start strong. Study with purpose.

Save up to 25% on trusted learning resources

Shop now

Description

Metabolomic Phenotyping for the Future of Personalized Medicine: Beyond the Biomarkers takes a critical look at the advancements in the field. It begins by explaining the essential steps of metabolomics analysis—from sample collection to data interpretation—while exploring how these workflows pave the way for targeted medical applications. With a focus on precision, it shows how metabolomics provides key insights into the mechanisms behind diverse phenotypes, making it an indispensable asset for biomedical research. The second section dives into the transformative results achieved in major medical domains through metabolomics, detailing how this emerging science contributes to understanding complex disease mechanisms.

The book also outlines the international regulatory framework essential for conducting research within this field, ensuring compliance and ethical standards. By combining practical guidelines with visionary insights, this text serves as a cornerstone for future strides in personalized medicine and highlights the growing influence of metabolomics in shaping tomorrow’s healthcare systems.

Key features

• Covers the complete metabolomics pipeline, from sample collection to data interpretation
• Describes how metabolic profiles reveal disease-specific signatures and guide clinical decisions
• Examines the European and U.S. regulatory landscape for AI and machine learning tools in public health
• Designed to engage professionals from multiple domains, including life sciences, clinical research, data science, and regulatory affairs

Readership

Academic researchers working in biochemistry, molecular biology, analytical chemistry, medical and pharmaceutical sciences, Industry professionals in the pharmaceutical and biotechnology industries, where metabolomics is attracting increasing interest; could also be of interest to physicians and surgeons engaged in research

Table of contents

1. Metabolomics in system biology

2. The metabolomics workflow: Fundamentals of chemical analysis

3. Data analysis approaches in untargeted metabolomics

4. Targeted metabolomics in investigating human diseases

5. Biomarker discovery: Pros and cons

6. Metabolomic profiling in screening and prognosis

7. Personalized medicine approaches: Interpreting the metabolome

8. Prenatal medicine: Metabolomics contribution and future targets

9. Metabolomics in the study of autoimmune diseases: Evidence and perspectives

10. From neurodevelopmental to neurodegenerative disorders: Insights from the metabolome lens

11. Cancer metabolomics: Is cancer a metabolic disease?

12. International normative aspects

13. Future perspectives

Product details

  • Edition: 1
  • Latest edition
  • Published: September 30, 2026
  • Language: English

About the authors

JT

Jacopo Troisi

Author of more than 100 papers in international peer-reviewed journals, holder of several international patents, and speaker at dozen international conferences, Jacopo Troisi is an award-winning expert in the metabolomics field. After graduating Summa cum Laude in biotechnology, he joined Medical School in the prestigious “Scuola Medica Salernitana” at the University of Salerno (Italy). He also attended and completed studies in data analysis. Currently, he is a visiting professor of Metabolomics in both Salerno and Sannio Universities (Italy), cofounder and CEO at Theoreo Srl, spin-off company of the University of Salerno, and COO at the European Biomedical Research Institute of Salerno (EBRIS). His research interests are mainly focused on metabolomic profiling to provide insights in human disease onset and for the development of diagnostic tools.
Affiliations and expertise
Research Scientist and COO, European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy, CEO, Theoreo srl – Salerno, Italy

ML

Martina Lombardi

Martina Lombardi is currently serves as Chief Scientific Officer at Theoreo srl, a spin-off company of the University of Salerno that deals with metabolomics, specifically the use of metabolomic profiling for the development of screening tests for human diseases. She also works at the “AOU Ruggi D'aragona” University Hospital in Salerno, Italy, where she was awarded a fellowship in internal medicine to study specifically the mechanisms underlying the progression of non-alcoholic fatty liver disease (NAFLD) and its association with metabolic syndrome and cardiovascular risk. She has published various papers in international peer-reviewed journals and presented her research results at metabolomic and bioinformatics and computational biology international conferences. She is currently actively engaged in the development of screening tests based on metabolomic profiling for various diseases, focusing mainly on oncological diseases and is part of the scientific committee of a national conference on applications of metabolomic profiling in endometrial cancer screening.
Affiliations and expertise
Chief Scientific Officer, Theoreo srl, Montecorvino Pugliano Salerno, SA, Italy